Abstract
Arylamine N-acetyltransferases (NAT) are xenobiotic-metabolizing enzymes responsible for the acetylation of many aromatic arylamine and heterocyclic amines, thereby playing an important role in both detoxification and activation of numerous drugs and carcinogens. Two closely related isoforms (NAT1 and NAT2) have been described in humans. NAT2 is mainly expressed in liver and gut, whereas NAT1 is found in a wide range of tissues. Interindividual variations in NAT genes have been shown to be a potential source of pharmacological and/or pathological susceptibility. In addition, there is now evidence that non genetic factors, such as substratedependent inhibition, drug interactions or cellular redox conditions may also contribute to NAT activity. The recent findings reviewed here provide possible mechanisms by which these environmental determinants may affect NAT activity. Interestingly, these data could contribute to the development of selective NAT inhibitors for the treatment of cancer and microbial diseases.
Keywords: N-acetyltransferases, xenobiotics, catalytic mechanism, covalent modifications, inhibition
Current Drug Metabolism
Title: Effect of Environmental Substances on the Activity of Arylamine N-Acetyltransferases
Volume: 9 Issue: 6
Author(s): Fernando Rodrigues-Lima, Julien Dairou and Jean-Marie Dupret
Affiliation:
Keywords: N-acetyltransferases, xenobiotics, catalytic mechanism, covalent modifications, inhibition
Abstract: Arylamine N-acetyltransferases (NAT) are xenobiotic-metabolizing enzymes responsible for the acetylation of many aromatic arylamine and heterocyclic amines, thereby playing an important role in both detoxification and activation of numerous drugs and carcinogens. Two closely related isoforms (NAT1 and NAT2) have been described in humans. NAT2 is mainly expressed in liver and gut, whereas NAT1 is found in a wide range of tissues. Interindividual variations in NAT genes have been shown to be a potential source of pharmacological and/or pathological susceptibility. In addition, there is now evidence that non genetic factors, such as substratedependent inhibition, drug interactions or cellular redox conditions may also contribute to NAT activity. The recent findings reviewed here provide possible mechanisms by which these environmental determinants may affect NAT activity. Interestingly, these data could contribute to the development of selective NAT inhibitors for the treatment of cancer and microbial diseases.
Export Options
About this article
Cite this article as:
Rodrigues-Lima Fernando, Dairou Julien and Dupret Jean-Marie, Effect of Environmental Substances on the Activity of Arylamine N-Acetyltransferases, Current Drug Metabolism 2008; 9 (6) . https://dx.doi.org/10.2174/138920008784892092
DOI https://dx.doi.org/10.2174/138920008784892092 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
<i>Ralstonia Mannitolilytica</i>, an Unusual Pathogen in the Neonatal Intensive Care Unit: A Case of Neonatal Sepsis and Literature Review
Infectious Disorders - Drug Targets Meet Our Associate Editor
Current Protein & Peptide Science Inhibitors of the Proteolytic Activity of Urokinase Type Plasminogen Activator
Current Pharmaceutical Design A Review on Anti-urease Potential of Coumarins
Current Drug Targets Possible Predictive Value of Maspin Expression in Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery HER-2 Positive Breast Cancer: What Else Beyond Trastuzumab-Based Therapy?
Anti-Cancer Agents in Medicinal Chemistry Hybrid SPECT/CT Imaging in Neurology
Current Radiopharmaceuticals Amino Acid Transporter ATB0,+ as a Delivery System for Drugs and Prodrugs
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Resveratrol and Its Analogues: Promising Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Metabolomics as a Tool for Drug Discovery and Personalised Medicine. A Review
Current Topics in Medicinal Chemistry Prevention and Treatment of Regimen-Related Mucosal Toxicity
Recent Patents on Anti-Cancer Drug Discovery Inhibitors for Proteins Endowed with Catalytic and Non-Catalytic Activity which Recognize pTyr
Current Medicinal Chemistry Clomiphene Citrate, Metformin or Both for Ovulation Induction in Therapy Naïve Women with Polycystic Ovary Syndrome (PCOS)? A Descriptive Review
Current Drug Therapy Imaging of Muscarinic Receptors in the Central Nervous System
Current Pharmaceutical Design Molecular Imaging in Optical Coherence Tomography
Current Molecular Imaging (Discontinued) Molecular Imaging Kits for Hexosamine Biosynthetic Pathway in Oncology
Current Medicinal Chemistry Differential Role of Apoptosis and Autophagy Associated with Anticancer Effect of Lupulone (Hop β-Acid) Derivatives on Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry The Tachykinergic System as Avenues for Drug Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Potential Non-coding RNAs from Microorganisms and their Therapeutic Use in the Treatment of Different Human Cancers
Current Gene Therapy